WallStSmart

BrightSpring Health Services, Inc. Common Stock (BTSG)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 429% more annual revenue ($72.25B vs $13.65B). LLY leads profitability with a 35.0% profit margin vs 2.3%. LLY trades at a lower P/E of 41.8x. LLY earns a higher WallStSmart Score of 76/100 (B+).

BTSG

Buy

53

out of 100

Grade: C-

Growth: 8.7Profit: 5.5Value: 4.0Quality: 6.0
Piotroski: 5/9Altman Z: 2.59

LLY

Strong Buy

76

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 4.3Quality: 6.0
Piotroski: 6/9Altman Z: 2.06

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTSG2 strengths · Avg: 9.0/10
EPS GrowthGrowth
359.8%10/10

Earnings expanding 359.8% YoY

Revenue GrowthGrowth
25.6%8/10

Revenue surging 25.6% year-over-year

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$1.02T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

Areas to Watch

BTSG4 concerns · Avg: 2.8/10
Profit MarginProfitability
2.3%3/10

2.3% margin — thin

Operating MarginProfitability
3.4%3/10

Operating margin of 3.4%

Debt/EquityHealth
1.363/10

Elevated debt levels

P/E RatioValuation
88.5x2/10

Premium valuation, high expectations priced in

LLY4 concerns · Avg: 2.8/10
PEG RatioValuation
1.584/10

Expensive relative to growth rate

Debt/EquityHealth
1.393/10

Elevated debt levels

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Price/BookValuation
34.7x2/10

Trading at 34.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : BTSG

The strongest argument for BTSG centers on EPS Growth, Revenue Growth. Revenue growth of 25.6% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bear Case : BTSG

The primary concerns for BTSG are Profit Margin, Operating Margin, Debt/Equity. A P/E of 88.5x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.

Bear Case : LLY

The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

BTSG carries more volatility with a beta of 1.79 — expect wider price swings.

LLY is growing revenue faster at 55.5% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (76/100 vs 53/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BrightSpring Health Services, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

BrightSpring Health Services, Inc. (BTSG) is a leading provider of home and community-based health services, focusing on diverse patient populations, including individuals with intellectual and developmental disabilities and those in need of rehabilitation support. The company prioritizes personalized, high-quality care, facilitated by a dedicated and skilled workforce that significantly improves patient outcomes and quality of life. With robust investments in innovative technologies and a strong commitment to value-based care, BrightSpring is well-positioned to capitalize on growth opportunities within the dynamic healthcare landscape, highlighting its potential for sustainable, long-term success.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?